DK173735B1 - Anvendelse af en knoglecelleaktiverende forbindelse og et knogleresorptionshæmmende polyphosphonat samt eventuelt en placeboforbindelse eller et næringssubstrat .......... - Google Patents

Anvendelse af en knoglecelleaktiverende forbindelse og et knogleresorptionshæmmende polyphosphonat samt eventuelt en placeboforbindelse eller et næringssubstrat .......... Download PDF

Info

Publication number
DK173735B1
DK173735B1 DK198501935A DK193585A DK173735B1 DK 173735 B1 DK173735 B1 DK 173735B1 DK 198501935 A DK198501935 A DK 198501935A DK 193585 A DK193585 A DK 193585A DK 173735 B1 DK173735 B1 DK 173735B1
Authority
DK
Denmark
Prior art keywords
diphosphonic acid
bone
hydroxy
daily dose
amino
Prior art date
Application number
DK198501935A
Other languages
Danish (da)
English (en)
Other versions
DK193585D0 (da
DK193585A (da
Inventor
Vernon Albert Uchtman
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of DK193585D0 publication Critical patent/DK193585D0/da
Publication of DK193585A publication Critical patent/DK193585A/da
Application granted granted Critical
Publication of DK173735B1 publication Critical patent/DK173735B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Debugging And Monitoring (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)
  • Surgical Instruments (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Processing Of Solid Wastes (AREA)
  • Medicines Containing Plant Substances (AREA)
DK198501935A 1984-04-30 1985-04-30 Anvendelse af en knoglecelleaktiverende forbindelse og et knogleresorptionshæmmende polyphosphonat samt eventuelt en placeboforbindelse eller et næringssubstrat .......... DK173735B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60554084A 1984-04-30 1984-04-30
US60554084 1984-04-30
US68456084A 1984-12-21 1984-12-21
US68456084 1984-12-21

Publications (3)

Publication Number Publication Date
DK193585D0 DK193585D0 (da) 1985-04-30
DK193585A DK193585A (da) 1985-10-31
DK173735B1 true DK173735B1 (da) 2001-08-20

Family

ID=27084976

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198501935A DK173735B1 (da) 1984-04-30 1985-04-30 Anvendelse af en knoglecelleaktiverende forbindelse og et knogleresorptionshæmmende polyphosphonat samt eventuelt en placeboforbindelse eller et næringssubstrat ..........

Country Status (12)

Country Link
EP (2) EP0162510B1 (de)
JP (1) JPH0655675B2 (de)
AT (2) ATE114473T1 (de)
AU (1) AU584611B2 (de)
CA (1) CA1277233C (de)
DE (2) DE3583887D1 (de)
DK (1) DK173735B1 (de)
FI (1) FI851686L (de)
HK (1) HK46694A (de)
IE (1) IE66497B1 (de)
NZ (1) NZ211925A (de)
PH (1) PH22622A (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU569391B2 (en) * 1984-04-30 1988-01-28 Procter & Gamble Company, The Treating osteoporosis
DE3514583A1 (de) * 1984-04-30 1985-10-31 The Procter & Gamble Co., Cincinnati, Ohio Verwendung eines zwei- oder mehrphasenmittels zur behandlung oder verhinderung von osteoporose
GR861167B (en) * 1985-05-02 1986-09-30 Research Corp Bone targeted inhibitors of carbonic anhydrase
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
CA2035179C (en) * 1990-01-31 2001-08-14 Gerald S. Brenner Pharmaceutical compositions containing insoluble salts of bisphosphonic acids
CA2101275C (en) * 1991-02-26 1998-08-04 Jocelyn Elaine Mcosker Methods for the treatment of osteoporosis
EP0550385A1 (de) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Peroral zu verabreichende pharmazeutische Zusammensetzungen, die Methandiphosphonsäure-Derivate und 18-Krone-6 Ether enthalten
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
WO1996007417A1 (en) * 1994-09-09 1996-03-14 The Procter & Gamble Company Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone
FR2727629A1 (fr) * 1994-12-06 1996-06-07 Sanofi Sa Trousse pour cycle de traitement de l'osteoporose
BR9510123A (pt) * 1994-12-28 1997-12-30 Gador Sa Composição anabólica da massa óssea
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
AR013994A1 (es) * 1998-10-30 2001-01-31 Gador Sa Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.
AU1525700A (en) * 1998-11-19 2000-06-05 Board Of Trustees Of The University Of Arkansas, The Increasing bone strength with selected bisphosphonates
US6121253A (en) * 1998-11-20 2000-09-19 Merck Frosst Canada & Co. Prostaglandin conjugates for treating or preventing bone disease
EP1158987A1 (de) * 1999-03-05 2001-12-05 The Procter & Gamble Company Verfahren zur erhohung des knochenvolumens mittels nicht natürlich vorkommenden fp agonisten und antiresorptiva
US8052987B2 (en) 2000-06-20 2011-11-08 Novartis Pharmaceuticals Corporation Method of administering bisphosphonates
EP1317247A1 (de) * 2000-09-13 2003-06-11 The Procter & Gamble Company Kosmetisches verfahren zur behandlung der haut und/oder haare
EP3345607B1 (de) 2006-12-29 2022-10-26 Ossifi-Mab LLC Verfahren zur veränderung des knochenwachstums durch verabreichung von sost- oder wise-antagonisten oder agonisten

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3683080A (en) * 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
US4330537A (en) * 1977-12-07 1982-05-18 The Procter & Gamble Company Compositions for inhibiting mobilization of calcium phosphate in animal tissue
US4230700A (en) * 1977-12-07 1980-10-28 The Procter & Gamble Company Methods for inhibiting mobilization of calcium phosphate in animal tissue
DE3514583A1 (de) * 1984-04-30 1985-10-31 The Procter & Gamble Co., Cincinnati, Ohio Verwendung eines zwei- oder mehrphasenmittels zur behandlung oder verhinderung von osteoporose
AU569391B2 (en) * 1984-04-30 1988-01-28 Procter & Gamble Company, The Treating osteoporosis

Also Published As

Publication number Publication date
DE3587956D1 (de) 1995-01-12
DK193585D0 (da) 1985-04-30
EP0381296A1 (de) 1990-08-08
AU4176985A (en) 1985-11-07
JPH0655675B2 (ja) 1994-07-27
EP0381296B1 (de) 1994-11-30
CA1277233C (en) 1990-12-04
EP0162510A1 (de) 1985-11-27
DK193585A (da) 1985-10-31
NZ211925A (en) 1989-01-06
IE66497B1 (en) 1996-01-10
JPS6133117A (ja) 1986-02-17
DE3583887D1 (de) 1991-10-02
HK46694A (en) 1994-05-20
AU584611B2 (en) 1989-06-01
FI851686A0 (fi) 1985-04-29
FI851686L (fi) 1985-10-31
EP0162510B1 (de) 1991-08-28
PH22622A (en) 1988-10-28
DE3587956T2 (de) 1995-05-24
IE851084L (en) 1985-10-30
ATE66608T1 (de) 1991-09-15
ATE114473T1 (de) 1994-12-15

Similar Documents

Publication Publication Date Title
DK173735B1 (da) Anvendelse af en knoglecelleaktiverende forbindelse og et knogleresorptionshæmmende polyphosphonat samt eventuelt en placeboforbindelse eller et næringssubstrat ..........
DK174584B1 (da) Kit til anvendelse i osteporosekur og anvendelse af polyphosphonat til fremstilling af kit
US4812311A (en) Kit for use in the treatment of osteoporosis
Kleerekoper The role of fluoride in the prevention of osteoporosis
Dixon et al. Synthetic D (-) penicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low dosage regimen.
KOPPEL et al. Thiazide-lnduced Rise in Serum Calcium and Magnesium in Patients on Maintenance Hemodialysis
Avioli The therapeutic approach to hypoparathyroidism
US4812304A (en) Treatment of osteoporosis
Mallette et al. Cyclic therapy of osteoporosis with neutral phosphate and brief, high‐dose pulses of etidronate
Hesch et al. Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1–38) hPTH and diphosphonate EHDP: Protocol of study I, osteoporosis trial Hannover
Parsons et al. The use of sodium fluoride, vitamin D and calcium supplements in the treatment of patients with axial osteoporosis
Kleerekoper et al. Comparative safety of bone remodeling agents with a focus on osteoporosis therapies
Schwille et al. Citrate and recurrent idiopathic calcium urolithiasis: a longitudinal pilot study on the metabolic effects of oral potassium citrate administered over the short-, medium-and long-term medication of male stone patients
Cook et al. Phytoestrogen and multiple vitamin/mineral effects on bone mineral density in early postmenopausal women: a pilot study
Goddard et al. Short-term effects of calcium carbonate, lactate, and gluconate on the calcium-parathyroid axis in normal elderly men and women
Grynpas et al. The action of fluoride on bone
Licata et al. Treatment of hyperparathyroidism with etidronate disodium
Praet et al. Comparative study of the intestinal absorption of three salts of calcium in young and elderly women
Féraille et al. Insulin unresponsiveness of tubular monovalent cation transport during fructose-induced hypertension in rats
Sjoden et al. Calcium absorption and excretion in patients treated with verapamil.
Cushner et al. Renal osteodystrophy—pathogenesis and treatment
Cunningham et al. Medical therapy in chronic kidney disease
Tschöpe et al. Hypercalciuria and nephrolithiasis
Peavy Endocrine regulation of calcium, phosphate, and bone metabolism
Munshi et al. Coexisting Osteoporosis and Vitamin D Deficiency-Double Trouble!

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed

Country of ref document: DK